Suppr超能文献

壳聚糖纳米粒用于增强乙型肝炎感染免疫

Chitosan-based nanoparticles for improving immunization against hepatitis B infection.

机构信息

Nanobiofar Group, Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

出版信息

Vaccine. 2010 Mar 19;28(14):2607-14. doi: 10.1016/j.vaccine.2010.01.011. Epub 2010 Jan 20.

Abstract

The design of effective vaccine delivery vehicles is opening up new possibilities for making immunization more equitable, safe and efficient. In this work, we purpose polysaccharidic-based nanoparticles as delivery structures for virus-like particle antigens, using recombinant hepatitis B surface antigen (rHBsAg) as a model. Polysaccharidic-based nanoparticles were prepared using a very mild ionic gelation technique, by cross-linking the polysaccharide chitosan (CS) with a counter ion. The resulting nanoparticles could be easily isolated with a size in the nanometric range (160-200 nm) and positive surface charge (+6 to +10 mV). More importantly, CS-based nanoparticles allowed the efficient association of the antigen (>60%) while maintaining the antigenic epitope intact, as determined by ELISA and Western blot. The entrapped antigen was further released in vitro from the nanoparticles in a sustained manner without compromising its antigenicity. In addition, loaded CS-based nanoparticles were stable, and protected the associated antigen during storage, either as an aqueous suspension under different temperature conditions (+4 degrees C and -20 degrees C), or as a dried form after freeze-drying the nanoparticles. Finally, immunization studies showed the induction of important seroprotection rates after intramuscular administration of the nanoparticles, indicating their adjuvant capacity. In fact, CS-based nanoparticles were able to induce anti-HBsAg IgG levels up to 5500 mIU/ml, values 9-fold the conventional alum-adsorbed vaccine. In conclusion, we report here a polysaccharidic nanocarrier which exhibits a number of in vitro and in vivo features that make it a promising adjuvant for vaccine delivery of subunit antigens.

摘要

有效的疫苗输送载体的设计为实现免疫接种更加公平、安全和高效开辟了新的可能性。在这项工作中,我们将多糖纳米颗粒作为病毒样颗粒抗原的输送结构,以重组乙型肝炎表面抗原(rHBsAg)为模型。多糖纳米颗粒是通过使用非常温和的离子凝胶技术制备的,该技术通过将多糖壳聚糖(CS)与反离子交联。所得纳米颗粒可以很容易地通过纳米级(160-200nm)和正表面电荷(+6 至+10mV)的尺寸进行分离。更重要的是,CS 基纳米颗粒允许抗原高效结合(>60%),同时保持抗原表位完整,如通过 ELISA 和 Western blot 确定。包封的抗原可以在体外以持续的方式从纳米颗粒中释放出来,而不会损害其抗原性。此外,负载 CS 基纳米颗粒在储存过程中是稳定的,并保护结合的抗原,无论是在不同温度条件(+4°C 和-20°C)下作为水性悬浮液,还是在纳米颗粒冷冻干燥后作为干燥形式。最后,免疫研究表明,经肌肉内给予纳米颗粒后,可诱导重要的血清保护率,表明其具有佐剂作用。事实上,CS 基纳米颗粒能够诱导高达 5500mIU/ml 的抗-HBsAg IgG 水平,是传统铝吸附疫苗的 9 倍。总之,我们在这里报告了一种多糖纳米载体,它表现出许多体外和体内特征,使其成为亚单位抗原疫苗输送的有前途的佐剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验